Hearing Evercore ISI Reiterating A $45 Price Target On Adamas Pharma, Following News Tues. Phase 3 Trial Of ADS-5102 Did Not Meet Primary Endpoint, Firm Highlights Belief Issue With Trial Could Be 'the final of many mistakes from prior mgmt...'